Clinical Use of the Urine Biomarker [TIMP-2] × [IGFBP7] for Acute Kidney Injury Risk Assessment

on behalf of the American Society of Nephrology Acute Kidney Injury Advisory Group

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Acute kidney injury (AKI) is a serious complication, commonly occurring in the critically ill population, with devastating short- and long-term consequences. Despite standardization of the definition and staging of AKI, early recognition remains challenging given that serum creatinine level is a marker, albeit imperfect, of kidney function and not kidney injury. Furthermore, the delay in increase in serum creatinine level after loss of glomerular filtration also prevents timely detection of decreased kidney function in patients with AKI. During the past decade, numerous clinical investigations have evaluated the utility of several biomarkers in the early diagnosis and risk stratification of AKI. In 2014, the US Food and Drug Administration approved the marketing of a test based on the combination of urine concentrations of tissue inhibitor of metalloproteinase 2 and insulin-like growth factor binding protein 7 ([TIMP-2] × [IGFBP7]) to determine whether certain critically ill patients are at risk for developing moderate to severe AKI. The optimal role of this biomarker in the diagnosis, management, and prognosis of AKI in different clinical settings requires further clarification. In this perspective, we summarize the biological actions of these 2 cell-cycle arrest biomarkers and present important considerations regarding the clinical application, interpretation, and limitations of this novel test for the early detection of AKI.

Original languageEnglish (US)
Pages (from-to)19-28
Number of pages10
JournalAmerican Journal of Kidney Diseases
Volume68
Issue number1
DOIs
StatePublished - Jul 1 2016

Fingerprint

Tissue Inhibitor of Metalloproteinase-2
Acute Kidney Injury
Biomarkers
Urine
Kidney
Critical Illness
Creatinine
United States Food and Drug Administration
Cell Cycle Checkpoints
insulin-like growth factor binding protein-related protein 1
Marketing
Serum
Early Diagnosis
Wounds and Injuries
Population

Keywords

  • Acute kidney injury (AKI)
  • biomarker
  • critically ill
  • decreased kidney function
  • diagnosis
  • early detection
  • insulin-like growth factor binding protein 7
  • NephroCheck
  • renal dysfunction
  • risk assessment
  • tissue inhibitor of metalloproteinase 2
  • [TIMP-2] × [IGFBP7]

ASJC Scopus subject areas

  • Nephrology

Cite this

Clinical Use of the Urine Biomarker [TIMP-2] × [IGFBP7] for Acute Kidney Injury Risk Assessment. / on behalf of the American Society of Nephrology Acute Kidney Injury Advisory Group.

In: American Journal of Kidney Diseases, Vol. 68, No. 1, 01.07.2016, p. 19-28.

Research output: Contribution to journalArticle

on behalf of the American Society of Nephrology Acute Kidney Injury Advisory Group 2016, 'Clinical Use of the Urine Biomarker [TIMP-2] × [IGFBP7] for Acute Kidney Injury Risk Assessment', American Journal of Kidney Diseases, vol. 68, no. 1, pp. 19-28. https://doi.org/10.1053/j.ajkd.2015.12.033
on behalf of the American Society of Nephrology Acute Kidney Injury Advisory Group. / Clinical Use of the Urine Biomarker [TIMP-2] × [IGFBP7] for Acute Kidney Injury Risk Assessment. In: American Journal of Kidney Diseases. 2016 ; Vol. 68, No. 1. pp. 19-28.
@article{250448317b5749939fb737ffe33bfbda,
title = "Clinical Use of the Urine Biomarker [TIMP-2] × [IGFBP7] for Acute Kidney Injury Risk Assessment",
abstract = "Acute kidney injury (AKI) is a serious complication, commonly occurring in the critically ill population, with devastating short- and long-term consequences. Despite standardization of the definition and staging of AKI, early recognition remains challenging given that serum creatinine level is a marker, albeit imperfect, of kidney function and not kidney injury. Furthermore, the delay in increase in serum creatinine level after loss of glomerular filtration also prevents timely detection of decreased kidney function in patients with AKI. During the past decade, numerous clinical investigations have evaluated the utility of several biomarkers in the early diagnosis and risk stratification of AKI. In 2014, the US Food and Drug Administration approved the marketing of a test based on the combination of urine concentrations of tissue inhibitor of metalloproteinase 2 and insulin-like growth factor binding protein 7 ([TIMP-2] × [IGFBP7]) to determine whether certain critically ill patients are at risk for developing moderate to severe AKI. The optimal role of this biomarker in the diagnosis, management, and prognosis of AKI in different clinical settings requires further clarification. In this perspective, we summarize the biological actions of these 2 cell-cycle arrest biomarkers and present important considerations regarding the clinical application, interpretation, and limitations of this novel test for the early detection of AKI.",
keywords = "Acute kidney injury (AKI), biomarker, critically ill, decreased kidney function, diagnosis, early detection, insulin-like growth factor binding protein 7, NephroCheck, renal dysfunction, risk assessment, tissue inhibitor of metalloproteinase 2, [TIMP-2] × [IGFBP7]",
author = "{on behalf of the American Society of Nephrology Acute Kidney Injury Advisory Group} and Anitha Vijayan and Sarah Faubel and Askenazi, {David J.} and Jorge Cerda and Fissell, {William H.} and Michael Heung and Humphreys, {Benjamin D.} and Koyner, {Jay L.} and Liu, {Kathleen D.} and Girish Mour and Nolin, {Thomas D.} and Azra Bihorac and Basu, {Rajit K.} and Bhatt, {Udayan Y.} and Connor, {Michael J.} and Davidson, {Alan J.} and {De Caestecker}, {Mark P.} and Kent Doi and Ladan Golestaneh and Mour, {Girish K.} and Prabhleen Singh and Thakar, {Charuhas V.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1053/j.ajkd.2015.12.033",
language = "English (US)",
volume = "68",
pages = "19--28",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Clinical Use of the Urine Biomarker [TIMP-2] × [IGFBP7] for Acute Kidney Injury Risk Assessment

AU - on behalf of the American Society of Nephrology Acute Kidney Injury Advisory Group

AU - Vijayan, Anitha

AU - Faubel, Sarah

AU - Askenazi, David J.

AU - Cerda, Jorge

AU - Fissell, William H.

AU - Heung, Michael

AU - Humphreys, Benjamin D.

AU - Koyner, Jay L.

AU - Liu, Kathleen D.

AU - Mour, Girish

AU - Nolin, Thomas D.

AU - Bihorac, Azra

AU - Basu, Rajit K.

AU - Bhatt, Udayan Y.

AU - Connor, Michael J.

AU - Davidson, Alan J.

AU - De Caestecker, Mark P.

AU - Doi, Kent

AU - Golestaneh, Ladan

AU - Mour, Girish K.

AU - Singh, Prabhleen

AU - Thakar, Charuhas V.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Acute kidney injury (AKI) is a serious complication, commonly occurring in the critically ill population, with devastating short- and long-term consequences. Despite standardization of the definition and staging of AKI, early recognition remains challenging given that serum creatinine level is a marker, albeit imperfect, of kidney function and not kidney injury. Furthermore, the delay in increase in serum creatinine level after loss of glomerular filtration also prevents timely detection of decreased kidney function in patients with AKI. During the past decade, numerous clinical investigations have evaluated the utility of several biomarkers in the early diagnosis and risk stratification of AKI. In 2014, the US Food and Drug Administration approved the marketing of a test based on the combination of urine concentrations of tissue inhibitor of metalloproteinase 2 and insulin-like growth factor binding protein 7 ([TIMP-2] × [IGFBP7]) to determine whether certain critically ill patients are at risk for developing moderate to severe AKI. The optimal role of this biomarker in the diagnosis, management, and prognosis of AKI in different clinical settings requires further clarification. In this perspective, we summarize the biological actions of these 2 cell-cycle arrest biomarkers and present important considerations regarding the clinical application, interpretation, and limitations of this novel test for the early detection of AKI.

AB - Acute kidney injury (AKI) is a serious complication, commonly occurring in the critically ill population, with devastating short- and long-term consequences. Despite standardization of the definition and staging of AKI, early recognition remains challenging given that serum creatinine level is a marker, albeit imperfect, of kidney function and not kidney injury. Furthermore, the delay in increase in serum creatinine level after loss of glomerular filtration also prevents timely detection of decreased kidney function in patients with AKI. During the past decade, numerous clinical investigations have evaluated the utility of several biomarkers in the early diagnosis and risk stratification of AKI. In 2014, the US Food and Drug Administration approved the marketing of a test based on the combination of urine concentrations of tissue inhibitor of metalloproteinase 2 and insulin-like growth factor binding protein 7 ([TIMP-2] × [IGFBP7]) to determine whether certain critically ill patients are at risk for developing moderate to severe AKI. The optimal role of this biomarker in the diagnosis, management, and prognosis of AKI in different clinical settings requires further clarification. In this perspective, we summarize the biological actions of these 2 cell-cycle arrest biomarkers and present important considerations regarding the clinical application, interpretation, and limitations of this novel test for the early detection of AKI.

KW - Acute kidney injury (AKI)

KW - biomarker

KW - critically ill

KW - decreased kidney function

KW - diagnosis

KW - early detection

KW - insulin-like growth factor binding protein 7

KW - NephroCheck

KW - renal dysfunction

KW - risk assessment

KW - tissue inhibitor of metalloproteinase 2

KW - [TIMP-2] × [IGFBP7]

UR - http://www.scopus.com/inward/record.url?scp=84959467506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959467506&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2015.12.033

DO - 10.1053/j.ajkd.2015.12.033

M3 - Article

C2 - 26948834

AN - SCOPUS:84959467506

VL - 68

SP - 19

EP - 28

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 1

ER -